Core Laboratories enters its April 30 Q1 results with short sellers backing away from a still-elevated position — and options traders leaning meaningfully bullish.
The short-selling pressure, while high in absolute terms, is visibly easing. Short interest stands at 9.4% of the float, but that figure has fallen roughly 7.6% in a single week — the clearest sign yet that bears are reducing exposure ahead of the print. Availability in the lending market is tight, at around 22%, meaning there is still limited room for new shorts relative to the shares already on loan. Cost to borrow has held steady near 0.49% — barely changed on the week and well off its late-March highs — which confirms there is no fresh squeeze pressure building. The ORTEX short score of 72.8 places CLB in a small group of names with structurally high short interest, though the score has dipped from a recent peak near 74.4.
Options traders have moved in the opposite direction from short sellers. The put/call ratio has dropped to 0.12, well below its 20-day average of 0.13 and the lowest it has been in months — a reading that reflects heavier call-side activity rather than defensive hedging. At 1.36 standard deviations below that average, the options market is skewing more bullishly into the report than it has been through most of April.
The analyst community, however, is broadly cautious — and notably, its most recent formal actions are over six months old. The last available price targets from Stifel (Hold, $12) and Citigroup (Neutral, $13) both sit below the current price of $17.30. BofA holds an Underperform. The consensus mean target near $16.33 implies the stock has already run past where most on the Street expected it to be. The 12-month forward EPS growth score ranks in the 82nd percentile — well above the sector median — suggesting the fundamental earnings trajectory is more constructive than the ratings suggest. Against that, EPS momentum over the past 30 and 90 days is uninspiring, in the 43rd and 35th percentiles respectively, pointing to recent estimate drift rather than acceleration.
Institutional ownership tells an interesting story at the margin. Ariel Investments holds close to 30% of shares — a dominant concentrated position. Goldman Sachs Asset Management and CWA Asset Management Group both added materially in Q1, with CWA's reported increase of over 1.1 million shares among the largest single moves in the register. Taken together, the passive and fundamental holders are expanding their stakes even as short sellers trim theirs. Past earnings reactions offer context without a clear pattern: the April 2026 Q4 print produced a modest 2.5% gain on the day and 4% over five sessions, while the prior event in February 2026 saw the stock fall over 5% on the day and nearly 7.5% over the week. The result was the polar opposite of the one that followed.
The April 30 print will test whether the improving forward earnings picture justifies a stock that has already outrun analyst targets — and whether the retreating short sellers were right to get out of the way.
See the live data behind this article on ORTEX.
Open CLB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
